Pediatrix (MD) Raised Its Outlook Floor. Why Did Mizuho Downgrade? Farooq Fri, November 13, 2026 at 4:10 PM EST 4 min read MD -0.32% ^GSPC -0.40% ^IXIC -0.91% CL=F +0.28% ^DJI +0.10% Trade MD on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
We just published a list of the Sell Alert: 10 Stocks Analysts Downgraded on Wednesday and Pediatrix Medical Group (NYSE:MD) ranked 9th on this list.
Wall Street got a sharp reminder this month of how fast sentiment can turn. Last Thursday the S&P 500 lost 4.4%, its worst day since April 2025, after midterm election results raised fears that regulation could hurt the AI trade. The Nasdaq Composite fell into correction territory, roughly 11% below the record it set in early October.
A rally on lower oil prices offered some relief at the start of this week. Then inflation data reopened the wound. Consumer prices rose 0.4% in October, the third straight monthly gain of at least that size and a touch above the 0.3% economists had expected. The stock market was still nervous from the prior week's rout, and it showed. The S&P 500 fell 0.38% to 7,520.93, the Dow lost 0.30% and the Nasdaq Composite slid 0.74% on the news.
Federal Reserve Governor Christopher Waller said the central bank should raise interest rates in December and consider a half-point increase if inflation worsens. Dallas Fed President Lorie Logan went further, saying at least two more quarter-point hikes are needed to bring prices under control. Three straight monthly gains of 0.4% or more is the kind of streak that keeps rate-hike talk alive.
Traders have taken the message seriously. They now price roughly an 84% chance of a quarter-point December hike, after a week in which both the stock and bond markets swung hard.
Investors tracking how far some AI stocks have fallen can find more names in our ranking of oversold AI stocks that analysts see rebounding by more than half.
Technology shares have taken the brunt of it. Selling in semiconductor stocks reached its most extreme level since 2019 earlier this week, by Yahoo Finance's measure, as worries about regulation of the AI trade added to the pressure.
Wednesday brought a rebound. The S&P 500 climbed 1.31% to 7,619.38, the Nasdaq Composite gained 1.60%, and the Dow rose 0.49%. The Nasdaq Composite had slipped into correction territory only days earlier. One day of gains does not erase the damage from the prior week, and the inflation and rate questions behind the selloff are still open. The Dow finished the day at 52,486.49.
Investors comparing cheaper alternatives can start with our roundup of affordable stocks that Wall Street analysts favor.
For now, the Federal Reserve's December meeting is the date traders are watching, with a hike priced as the likely outcome.
Pediatrix made it to our list because it has an average upside potential of -4%. Pricing growth at Pediatrix Medical Group slowed to 0.3% in the third quarter from about 4% in each of the two before it. Mizuho took that as a warning. On November 11 the firm cut the stock to Underperform from Neutral and held its price target at $28. It argued that pricing gains have largely plateaued, which limits further upside to earnings per share. Healthcare services stocks have historically traded on volumes, Mizuho added.
Mizuho also pointed to the company's heavy exposure to the birth rate, a factor management cannot control. With inflation running hot and low birth rates expected, the firm sees little room for a meaningful volume recovery and expects Pediatrix volume growth to lag overall healthcare use.
Pediatrix provides neonatal and maternal-fetal physician services. It still reported adjusted earnings of $0.72 per share for the quarter and raised the floor of its full-year EBITDA outlook. A favorable mix of insurance payers has more than offset weak volumes this year. Our look at how earnings kept growing while patient volumes kept falling covers the setup behind this debate.
While we acknowledge the risk and potential of MD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: Nvidia (NVDA) Grows Like a Rocket But Still Looks Cheap and Akamai (AKAM) Wants to Be the Bouncer for Your AI Agents
Disclosure: None. Follow Insider Monkey on Google News.
